UPCNasdaqPharmaceutical PreparationsFiscal year ends September 30

Universe Pharmaceuticals INC

Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Jan 29, 2026

$3.76−0.17 (-4.33%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Universe Pharmaceuticals INC cash flow statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30	FY 2020 2020-09-30	FY 2019 2019-09-30
Depreciation & Amortization	517	486	509	0.53	0.45	0.41	0.42
Deferred Income Taxes	–	607	1,568	-0.54	-0.67	-0.01	-0.04
Change in Accounts Receivable	-169	-1,548	4,718	-1.53	-3.87	-4.11	0.67
Change in Inventory	-475	1,643	-1,184	0.02	-0.45	0.89	5.59
Change in Accounts Payable	-3,133	144	1,641	-1.92	2.46	0.64	-0.92
Change in Unearned Revenue	40	–	–	–	–	–	–
Operating Cash Flow	-5,052	-9,507	1,117	-1.30	-2.06	6.12	13
Capital Expenditures	-267	-208	-44	-0.09	-0.44	-0.05	-0.09
Acquisitions	–	–	–	-3.81	–	–	–
Sale of Property, Plant & Equipment	5.38	1.80	–	0.00	–	–	0.00
Purchase of Investments	–	–	–	–	-15	–	–
Investing Cash Flow	-342	-361	-44	-3.91	-27	-0.05	-0.09
Dividends Paid	–	–	–	–	–	–	-16
Stock Issued	15,000	25,000	–	–	–	–	–
Financing Cash Flow	9,726	33,954	-1,391	3.32	27	0.47	-16
Foreign Exchange Rate Adjustments	-238	126	-108	-0.47	0.55	0.35	-0.13
Net Change in Cash	4,094	24,212	-426	-2.37	-1.98	6.88	-3.01
Free Cash Flow	-5,319	-9,715	1,073	-1.40	-2.50	6.06	13
Income Taxes Paid	–	–	864	2.75	3.27	2.17	2.26
Interest Paid	289	305	190	0.20	0.15	0.16	0.14

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY2025

Gross margin: 35.3%
Operating margin: -16.3%
Net margin: -20.6%
Return on equity, FY2025: -7226.1%

Financial strength

Current ratio: 4.05
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 202.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –